ArriVent BioPharma, Inc.
AVBP
$22.86
$0.050.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -166.31M | -150.98M | -136.79M | -127.46M | -80.49M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.49M | 9.83M | 7.21M | 4.85M | 3.21M |
| Change in Net Operating Assets | -3.77M | -4.94M | 2.95M | 3.01M | 7.07M |
| Cash from Operations | -160.59M | -146.08M | -126.63M | -119.59M | -70.21M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -71.23M | -192.49M | -141.73M | -155.64M | -192.47M |
| Cash from Investing | -71.23M | -192.49M | -141.73M | -155.64M | -192.47M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 203.13M | 168.45M | 82.81M | 7.76M | 186.58M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -70.00K | -53.00K | -353.00K | -50.00K | -- |
| Cash from Financing | 203.06M | 168.39M | 82.46M | 7.71M | 186.58M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.75M | -170.18M | -185.90M | -267.53M | -76.10M |